Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Tadalafil Mylan
Tadalafil Mylan 10 mg film-coated tablets Tadalafil Mylan 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-131479 · Präparat HOS-097067
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal products
were studied, including calcium channel blockers (amlodipine), angiotensin converting enzyme (ACE)
inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendroflumethiazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose was
applied) had no clinically significant interaction with any of these classes. In another clinical pharmacology
study tadalafil (20 mg) was studied in combination with up to 4 classes of antihypertensives. In subjects
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) enalapril (HOS-085479) bendroflumethiazide (HOS-131387) amlodipine (HOS-086287) calcium (HOS-085615) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T12:38:00Z · SHA-256 2c06d7b4e73c05361baf5d12e4bb06aa9f06b0ce1a899ac34068fb6b554e7343 · Passage 27b82ffa3277aa1f27fdf38e283412d8dd7687d67a46638eccb552a008b9a330 · Zeichen 3708–4623 im Abschnitt
Wechselwirkungen · Tadalafil Lilly
Tadalafil Lilly 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-140432 · Präparat HOS-098526
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal
products were studied, including calcium channel blockers (amlodipine), angiotensin converting
enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose
was applied) had no clinically significant interaction with any of these classes. In another clinical
pharmacology study tadalafil (20 mg) was studied in combination with up to 4 classes of
antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure
changes appeared to relate to the degree of blood-pressure control. In this regard, study subjects whose
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) enalapril (HOS-085479) amlodipine (HOS-086287) calcium (HOS-085615) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:35:00Z · SHA-256 591c030e92917080839aac0522f89e39ae339bcc4be9e68371f7969a185b0857 · Passage 10c5a5e47efdaf35c48c86e2a7105e99cd462db2bc1c21babeba9747c683c1e6 · Zeichen 3743–4823 im Abschnitt
Wechselwirkungen · Tadalafil Lilly
Tadalafil Lilly 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-140485 · Präparat HOS-098526
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal
products were studied, including calcium channel blockers (amlodipine), angiotensin converting
enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose
was applied) had no clinically significant interaction with any of these classes. In another clinical
pharmacology study tadalafil (20 mg) was studied in combination with up to 4 classes of
antihypertensives. In subjects taking multiple antihypertensives, the ambulatory-blood-pressure
changes appeared to relate to the degree of blood-pressure control. In this regard, study subjects whose
blood pressure was well controlled, the reduction was minimal and similar to that seen in healthy
subjects. In study subjects whose blood pressure was not controlled, the reduction was greater
although this reduction was not associated with hypotensive symptoms in the majority of subjects. In
patients receiving concomitant antihypertensive medicinal products, tadalafil 20 mg may induce a
blood pressure decrease, which (with the exception of alpha blockers -see above-) is, in general, minor
and not likely to be clinically relevant. Analysis of phase 3 clinical trial data showed no difference in
adverse events in patients taking tadalafil with or without antihypertensive medicinal products.
However, appropriate clinical advice should be given to patients regarding a possible decrease in
blood pressure when they are treated with antihypertensive medicinal products.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) enalapril (HOS-085479) amlodipine (HOS-086287) calcium (HOS-085615) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:35:00Z · SHA-256 591c030e92917080839aac0522f89e39ae339bcc4be9e68371f7969a185b0857 · Passage c0ae8045aff7f8a7fd05a121cf691a3f593453fda4a2a84d3dbb9c19b2f51831 · Zeichen 3744–5699 im Abschnitt
Wechselwirkungen · Tadalafil Lilly
Tadalafil Lilly 10 mg film-coated tablets Tadalafil Lilly 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 35
HOS-140526 · Präparat HOS-098526
In clinical pharmacology studies, the potential for tadalafil to augment the hypotensive effects of
antihypertensive medicinal products was examined. Major classes of antihypertensive medicinal
products were studied, including calcium channel blockers (amlodipine), angiotensin converting
enzyme (ACE) inhibitors (enalapril), beta-adrenergic receptor blockers (metoprolol), thiazide diuretics
(bendrofluazide), and angiotensin II receptor blockers (various types and doses, alone or in
combination with thiazides, calcium channel blockers, beta-blockers, and/or alpha-blockers). Tadalafil
(10 mg except for studies with angiotensin II receptor blockers and amlodipine in which a 20 mg dose
was applied) had no clinically significant interaction with any of these classes. In another clinical
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) enalapril (HOS-085479) amlodipine (HOS-086287) calcium (HOS-085615) metoprolol (HOS-090094)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T13:35:00Z · SHA-256 591c030e92917080839aac0522f89e39ae339bcc4be9e68371f7969a185b0857 · Passage 57be84187e4acfca3a70dac31089b839a7cb9e5e198d1c96d8c7b58e578ac0c5 · Zeichen 3741–4532 im Abschnitt
Wechselwirkungen · Bysumlog
Bysumlog 100 units/ml solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 5
HOS-151841 · Präparat HOS-100633
Insulin requirements may be reduced in the presence of medicinal products with hypoglycaemic
activity, such as oral hypoglycaemics, salicylates (for example, acetylsalicylic acid), sulpha
antibiotics, certain antidepressants (monoamine oxidase inhibitors, selective serotonin reuptake
inhibitors), certain angiotensin converting enzyme inhibitors (captopril, enalapril), angiotensin II
receptor blockers, beta-blockers, octreotide or alcohol.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) captopril (HOS-085478) enalapril (HOS-085479) octreotide (HOS-085481) serotonin (HOS-085477)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T10:04:00Z · SHA-256 55b4378e06080aa9c19550e9fbdf5f027aa4d385f9c95bdfeab2be376065de76 · Passage 4e12a07e73d8580a6bf214e9fee49b1a7dab7ea5a3fc8b8a8b1d339626193eea · Zeichen 241–683 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.